image
Healthcare - Medical - Devices - NASDAQ - US
$ 0.7695
-0.0649 %
$ 13.2 M
Market Cap
1.54
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one PAVM stock under the worst case scenario is HIDDEN Compared to the current market price of 0.769 USD, PAVmed Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one PAVM stock under the base case scenario is HIDDEN Compared to the current market price of 0.769 USD, PAVmed Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one PAVM stock under the best case scenario is HIDDEN Compared to the current market price of 0.769 USD, PAVmed Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
3 B REVENUE
122045.19%
-44.5 B OPERATING INCOME
-64566.04%
28.4 M NET INCOME
144.30%
-33.6 M OPERATING CASH FLOW
35.52%
-16.2 M INVESTING CASH FLOW
-2135.09%
31.3 M FINANCING CASH FLOW
0.36%
10 K REVENUE
-99.00%
-5.19 M OPERATING INCOME
55.20%
1.14 M NET INCOME
-98.23%
94 K OPERATING CASH FLOW
101.06%
-4 K INVESTING CASH FLOW
99.98%
330 K FINANCING CASH FLOW
16.20%
Balance Sheet PAVmed Inc.
image
Current Assets 2.16 B
Cash & Short-Term Investments 1.18 B
Receivables 18 K
Other Current Assets 979 M
Non-Current Assets 28.5 M
Long-Term Investments 0
PP&E 2.65 M
Other Non-Current Assets 25.8 M
54.05 %44.65 %
Current Liabilities 35.4 B
Accounts Payable 657 K
Short-Term Debt 29.6 M
Other Current Liabilities 35.4 B
Non-Current Liabilities 2.25 M
Long-Term Debt 2.25 M
Other Non-Current Liabilities 0
99.91 %
EFFICIENCY
Earnings Waterfall PAVmed Inc.
image
Revenue 3 B
Cost Of Revenue 4.84 B
Gross Profit -1.84 B
Operating Expenses 42.6 B
Operating Income -44.5 B
Other Expenses -44.5 B
Net Income 28.4 M
RATIOS
-61.60% GROSS MARGIN
-61.60%
-1485.38% OPERATING MARGIN
-1485.38%
1067.31% NET MARGIN
1067.31%
-1281.20% ROE
-1281.20%
104259.62% ROA
104259.62%
150.57% ROIC
150.57%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis PAVmed Inc.
image
Net Income 28.4 M
Depreciation & Amortization 1.2 M
Capital Expenditures 0
Stock-Based Compensation 6.45 M
Change in Working Capital 512 K
Others -69.6 M
Free Cash Flow -33.6 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets PAVmed Inc.
image
PAVM has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 9
6. Ownership
Insider Ownership PAVmed Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025 Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , May 1, 2025 /PRNewswire/ -- PAVmed Inc.  (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Thursday, May 15, 2025, at 8:30 AM ET. During the call,  Lishan Aklog, M.D. prnewswire.com - 2 weeks ago
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025 Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , April 30, 2025 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Wednesday, May 14, 2025, at 8:30 AM ET. During the call,  Lishan Aklog, M.D. prnewswire.com - 2 weeks ago
PAVmed (PAVM) Upgraded to Buy: Here's What You Should Know PAVmed (PAVM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 3 weeks ago
NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD Study supports expanded indication and market opportunity for EsoGuard esophageal precancer testing NEW YORK , April 24, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced positive data from a National Cancer Institute (NCI)-sponsored study demonstrating that its EsoGuard® Esophageal DNA Test can effectively detect esophageal precancer (Barrett's Esophagus or BE) among at-risk patients without symptoms of chronic gastroesophageal reflux disease (GERD), such as heartburn. These results support EsoGuard esophageal precancer testing in an expanded target population, consistent with existing American Gastroenterological Association (AGA) guidelines and has the potential to substantially increase the market opportunity. prnewswire.com - 3 weeks ago
Lucid Diagnostics Announces Closing of Public Offering of Common Stock NEW YORK , April 11, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the closing of its previously announced underwritten public offering of 14,375,000 shares of its common stock, including 1,875,000 shares issued pursuant to the exercise of the underwriters' option to purchase additional shares, at a public offering price of $1.20 per share. The total net proceeds from the offering, after deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $16.1 million. prnewswire.com - 1 month ago
Lucid Diagnostics Announces Pricing of Public Offering of Common Stock NEW YORK , April 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the pricing of its underwritten public offering of 12,500,000 shares of its common stock at a public offering price of $1.20 per share. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1,875,000 shares of common stock at the public offering price, less underwriting discounts and commissions. prnewswire.com - 1 month ago
Lucid Diagnostics Announces Proposed Public Offering of Common Stock NEW YORK , April 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced its intention to offer shares of common stock through an underwritten public offering. The Company also plans to grant the underwriters a 45-day option to purchase additional shares of common stock. prnewswire.com - 1 month ago
Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference NEW YORK , April 3, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that Lishan Aklog, M.D. , Lucid's Chairman and Chief Executive Officer, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10, 2025 at 11:00 AM EDT. prnewswire.com - 1 month ago
Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology Campaign will coincide with Esophageal Cancer Awareness Month and will be featured at the upcoming Digestive Disease Week (DDW) Conference NEW YORK , March 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced a campaign, entitled "Embrace the Future", designed to showcase its groundbreaking EsoCheck® Esophageal Cell Collection Device, with Collect+Protect™ Technology, to gastroenterologists and the broader medical community. The campaign will coincide with Esophageal Cancer Awareness Month this April and will be prominently featured at Digestive Disease Week (DDW) 2025, the world's premier meeting for gastroenterologists and other digestive disease professionals, to be held in May. prnewswire.com - 1 month ago
PAVmed Inc. (PAVM) Q4 2024 Earnings Call Transcript PAVmed Inc. (NASDAQ:PAVM ) Q4 2024 Earnings Conference Call March 25, 2025 8:30 AM ET Company Participants Matt Riley - Senior Director of IR Lishan Aklog - Chairman and CEO Dennis McGrath - CFO Conference Call Participants Jeremy Pearlman - Maxim Group Matthew Park - Cantor Fitzgerald Ed Woo - Ascendiant Capital Operator Good morning, and welcome to PAVmed's Fourth Quarter 2024 Business Update Conference Call. At this time, all lines are in a listen-only mode. seekingalpha.com - 1 month ago
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results Lucid processed record test volume, saw rapid initial uptake in concierge medicine contracts, and secured first commercial insurance coverage policies  Veris Health secured financing to resume advancement of implantable physiological monitor through FDA clearance and commercial launch  PAVmed completed debt restructuring and Lucid deconsolidation to regain Nasdaq compliance and strengthen balance sheet Conference call and webcast to be held today, March 25 th, at 8:30 AM EDT NEW YORK , March 25, 2025 /PRNewswire/ --  PAVmed Inc.  (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and reported financial results for the fourth quarter and full year ended December 31, 2024. Conference Call and Webcast The webcast will take place on Tuesday, March 25, 2025, at 8:30 AM and is accessible in the investor relations section of the Company's website at pavmed.com. prnewswire.com - 1 month ago
Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results Processed a record 4,042 EsoGuard tests in 4Q24, a 45% sequential and 84% annual increase Recognized EsoGuard revenue of $1.2 million in 4Q24   New sales channel generated over 20 new cash-pay concierge medicine contracts Secured first agreement to pay for EsoGuard under state biomarker legislation Conference call and webcast to be held today, March 24 th at 8:30 AM EDT NEW YORK , March 24, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today provided a business update for the Company and reported financial results for the fourth quarter and full year ended December 31, 2024. Conference Call and Webcast The webcast will take place on Monday, March 24, 2024, at 8:30 AM and will be accessible in the investor relations section of the Company's website at luciddx.com. prnewswire.com - 1 month ago
8. Profile Summary

PAVmed Inc. PAVM

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 13.2 M
Dividend Yield 0.00%
Description PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics; NextVent single-use ventilators; FlexMO medical circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; Solys noninvasive glucose monitoring. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
Contact One Grand Central Place, New York, NY, 10165 https://www.pavmed.com
IPO Date July 27, 2016
Employees 39
Officers Dr. Deepika A. Lakhani Ph.D. Senior Vice President, Chief Regulatory & Quality Officer Dr. Victoria T. Lee M.D. Senior Vice President & Chief Medical Officer Mr. Shaun M. O'Neill M.B.A. Executive Vice President & Chief Operating Officer Mr. Michael Adam Gordon Executive Vice President, General Counsel & Secretary Dr. Brian J. deGuzman M.D. Executive Vice President, Chief Technology & Compliance Officer Dr. Suman M. Verma M.D., Ph.D. Senior Vice President of Molecular Genetics & Chief Scientific Officer Dr. Lishan Aklog M.D. Chairman & Chief Executive Officer